
LIXTE Biotechnology Reports Transformational 2025 with Clinical Progress and Strategic Expansion
LIXTE Biotechnology Holdings' 2025 Form 10-K filing highlights significant clinical advancements for its lead cancer compound LB-100, strategic acquisitions, and financial strengthening, positioning the company for continued innovation in oncology treatments.
Read full story


























